# Marinus Pharmaceuticals clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Marinus Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Marinus Pharmaceuticals: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/marinus-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 18, 2023 | NCT05814523 | To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus... | Marinus Pharmaceuticals | Phase 3 | Withdrawn | Refractory Status Epilepticus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814523) |
| March 7, 2023 | NCT05757544 | Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) | Marinus Pharmaceuticals | Phase 2 | Withdrawn | Status Epilepticus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05757544) |
| November 3, 2022 | NCT05604170 | Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy | Marinus Pharmaceuticals | Phase 3 | Terminated | Tuberous Sclerosis Complex | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05604170) |
| April 12, 2022 | NCT05323734 | Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | Marinus Pharmaceuticals | Phase 3 | Completed | Tuberous Sclerosis Complex | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05323734) |
| December 22, 2020 | NCT04678479 | Ganaxolone Expanded Access Program Compassionate Use | Marinus Pharmaceuticals | Not applicable | No longer available | CDKL5 Disorder | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04678479) |
| May 18, 2020 | NCT04391569 | Randomized Therapy In Status Epilepticus | Marinus Pharmaceuticals | Phase 3 | Completed | Status Epilepticus | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04391569) |
| February 26, 2020 | NCT04285346 | Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | Marinus Pharmaceuticals | Phase 2 | Completed | Tuberous Sclerosis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04285346) |
| March 7, 2019 | NCT03865732 | Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study) | Marinus Pharmaceuticals | Phase 2 | Completed | PCDH19-Related Epilepsy | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03865732) |
| June 28, 2018 | NCT03572933 | Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder | Marinus Pharmaceuticals | Phase 3 | Completed | CDKL5 Deficiency Disorder | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03572933) |
| March 9, 2018 | NCT03460756 | A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression | Marinus Pharmaceuticals | Phase 2 | Completed | Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03460756) |
| November 22, 2017 | NCT03350035 | Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus | Marinus Pharmaceuticals | Phase 2 | Completed | Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03350035) |
| July 24, 2017 | NCT03228394 | A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression | Marinus Pharmaceuticals | Phase 2 | Completed | Depression, Depressive Disorder, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorders... | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03228394) |
| August 11, 2015 | NCT02519439 | A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures | Marinus Pharmaceuticals | Phase 3 | Terminated | Drug Resistant Partial Onset Seizure | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02519439) |
| February 9, 2015 | NCT02358538 | Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies | Marinus Pharmaceuticals | Phase 2 | Completed | Epilepsy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02358538) |
| October 16, 2013 | NCT01963208 | Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension | Marinus Pharmaceuticals | Phase 3 | Completed | Drug Resistant Partial Onset Seizure | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01963208) |
| November 12, 2012 | NCT01725152 | Ganaxolone Treatment in Children With Fragile X Syndrome | Marinus Pharmaceuticals | Phase 2 | Completed | Fragile x Syndrome | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01725152) |
| April 21, 2011 | NCT01339689 | Ganaxolone in Posttraumatic Stress Disorder (PTSD) | Marinus Pharmaceuticals | Phase 2 | Completed | PTSD | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01339689) |
| October 27, 2009 | NCT01002820 | A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 | Marinus Pharmaceuticals | Phase 2 | Completed | Epilepsy, Complex Partial | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01002820) |
| August 7, 2007 | NCT00512317 | Open-label Extension to Protocol 1042-0600 | Marinus Pharmaceuticals | Phase 2 | Completed | Epilepsies, Partial | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00512317) |
| April 25, 2007 | NCT00465517 | A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures | Marinus Pharmaceuticals | Phase 2 | Completed | Partial Epilepsy, Catamenial Epilepsy | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00465517) |
| March 1, 2007 | NCT00442104 | Open-label Extension to Protocol 1042-0500 | Marinus Pharmaceuticals | Phase 2 | Terminated | Infantile Spasms | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00442104) |
| March 1, 2007 | NCT00441896 | A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms | Marinus Pharmaceuticals | Phase 2 | Completed | Infantile Spasms | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00441896) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 14 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 3 |
| Withdrawn | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 9 |
| Seizures | 8 |
| Epilepsies, Partial | 4 |
| Status Epilepticus | 4 |
| Tuberous Sclerosis | 3 |
| CDKL5 deficiency disorder | 2 |
| Spasms, Infantile | 2 |
| Depression | 2 |
| Depressive Disorder | 2 |
| Depression, Postpartum | 2 |
| Behavioral Symptoms | 2 |
| Mood Disorders | 2 |
| Mental Disorders | 2 |
| Puerperal Disorders | 2 |
| Pregnancy Complications | 2 |
| Stress Disorders, Post-Traumatic | 1 |
| Fragile X Syndrome | 1 |
| Anxiety Disorders | 1 |
| Epilepsy, Complex Partial | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
- [Construction management firms in the United States](https://specstream.ai/data/businesses/construction-management-firms/united-states)
